Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03799523|
Recruitment Status : Recruiting
First Posted : January 10, 2019
Last Update Posted : February 28, 2019
|Condition or disease||Intervention/treatment|
|Breast Cancer||Other: Temporary skin markings Other: Surface imaging|
|Study Type :||Observational|
|Estimated Enrollment :||48 participants|
|Official Title:||Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy|
|Actual Study Start Date :||January 16, 2019|
|Estimated Primary Completion Date :||June 30, 2020|
|Estimated Study Completion Date :||January 30, 2021|
Subjects undergoing breast radiotherapy
At the time of CT simulation study participants will receive temporary skin markings to be covered in clear medical grade tape. Light-based surface imaging will be used to determine alignment between the patient and the radiation machine. Radiation treatment will proceed as standard of care.
Other: Temporary skin markings
To use temporary markings in lieu of localization tattoos.
Other: Surface imaging
To use light-based surface imaging for patient positioning during radiation treatment.
- Position measurement from Port films. [ Time Frame: Once weekly for 3 weeks up to 5 weeks ]Distance measured (centimeters) from the planned position of radiotherapy to the actual position of radiotherapy on weekly port films. Port films are x-rays of the treatment field which are done to ensure that the patient and the radiation machine are properly aligned to each other. Weekly port films will be obtained for the duration of radiation treatment, which will be from three to five weeks in length.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03799523
|Contact: Carol Jenkins, RNemail@example.com|
|United States, Texas|
|UT Health San Antonio Mays Cancer Center||Recruiting|
|San Antonio, Texas, United States, 78229|
|Contact: Angela Kennedy 210-450-6490 firstname.lastname@example.org|
|Principal Investigator: Richard Crownover, MD|
|Principal Investigator:||Richard Crownover, MD||Principal Investigator|